Captor Therapeutics is a biopharmaceutical company specializing in leveraging Targeted Protein Degradation (TPD) technology to develop drug candidates for severe conditions such as cancer and autoimmune diseases. Captor Therapeutics has developed a proprietary Optigradeᵀᴹ platform, a drug discovery engine, and an extensive library of degraders and glues. The company is focused on developing protein degradation drugs for cancer and autoimmune diseases, with a core pipeline project designated as CT-03 for the treatment of haematological, lung, and breast cancers.
Headquarters
ul. Dunska 11
Wroclaw; Dolnoslaskie;
Postal Code: 54-427
Contact Details: Purchase the Captor Therapeutics S.A. report to view the information.
Website: http://www.captortherapeutics.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service